1. Home
  2. ICFI vs JANX Comparison

ICFI vs JANX Comparison

Compare ICFI & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ICF International Inc.

ICFI

ICF International Inc.

HOLD

Current Price

$86.48

Market Cap

1.7B

ML Signal

HOLD

Logo Janux Therapeutics Inc.

JANX

Janux Therapeutics Inc.

HOLD

Current Price

$14.31

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ICFI
JANX
Founded
1969
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.8B
IPO Year
2006
2021

Fundamental Metrics

Financial Performance
Metric
ICFI
JANX
Price
$86.48
$14.31
Analyst Decision
Buy
Strong Buy
Analyst Count
4
12
Target Price
$98.00
$60.27
AVG Volume (30 Days)
155.2K
3.3M
Earning Date
10-30-2025
11-06-2025
Dividend Yield
0.65%
N/A
EPS Growth
N/A
N/A
EPS
5.30
N/A
Revenue
$1,925,502,000.00
$10,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$2.57
N/A
P/E Ratio
$16.32
N/A
Revenue Growth
N/A
N/A
52 Week Low
$72.03
$13.76
52 Week High
$135.34
$61.59

Technical Indicators

Market Signals
Indicator
ICFI
JANX
Relative Strength Index (RSI) 56.76 28.17
Support Level $84.24 $13.82
Resistance Level $87.24 $14.50
Average True Range (ATR) 2.68 0.63
MACD 0.16 -0.03
Stochastic Oscillator 59.69 15.32

Price Performance

Historical Comparison
ICFI
JANX

About ICFI ICF International Inc.

ICF International Inc provides professional services and technology-based solutions to government and commercial clients, including management, marketing, technology, and policy consulting and implementation services. Its services support clients that operate in four key markets that include Energy, Environment, Infrastructure and Disaster Recovery; Health and Social Programs and Security and Other Civilian & Commercial. The Company's majority clients are United States federal government departments and agencies. It operates in a single segment, which is providing professional services.

About JANX Janux Therapeutics Inc.

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

Share on Social Networks: